Response to Dr Norris and Dr McCulloch

Sir,

We thank Dr Norris and Dr McCulloch¹ for their interest in our paper² and for their very informative comments. We fully agree with them on the issues and potential difficulties in designing a randomised controlled trial (RCT) when one of the modalities of treatment (oral propranolol) has a very high ‘success’ rate in published literature. We have highlighted this in our paper under the subheading ‘areas for future research’. We collude with the authors on the need for an RCT to further explore dosage and duration of oral propranolol therapy and to monitor adverse effects.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account

Continue with Google

Continue with ORCiD